Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 5/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.36 |
| ▸ | HTT | P42858 | 2/20 | 0.36 |
| ▸ | PIK3CA | P42336 | 2/20 | 0.36 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.36 |
| ▸ | PIK3R1 | P27986 | 1/20 | 0.36 |
| ▸ | ADORA2A | P29274 | 2/20 | 0.35 |
| ▸ | PIK3CD | O00329 | 3/20 | 0.35 |
| ▸ | SLC29A1 | Q99808 | 1/20 | 0.35 |
| ▸ | PIK3CB | P42338 | 1/20 | 0.35 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.34 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.34 |
| ▸ | GAA | P10253 | 2/20 | 0.34 |
| ▸ | P2RX3 | P56373 | 2/20 | 0.34 |
| ▸ | MAPT | P10636 | 1/20 | 0.34 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.34 |
| ▸ | HPGD | P15428 | 2/20 | 0.33 |
| ▸ | NT5E | P21589 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25391427 | 0.85 | SLC29A1 (0.41) | PIK3CAHDAC1PIK3R1ADORA2APIK3CD | |
| SCHEMBL2674349 | 0.81 | PIK3CA (0.40) | KDM4EALDH1A1HTTPIK3CAHDAC1 | |
| SCHEMBL1192253 | 0.79 | MAPK1 (0.40) | KDM4EALDH1A1HTTHDAC1ADORA2A | |
| SCHEMBL2673378 | 0.79 | PIK3CD (0.46) | PIK3CAADORA2APIK3CDPIK3CB | |
| SCHEMBL2673601 | 0.79 | HTT (0.34) | HTTPIK3CAHDAC1PIK3CDSLC29A1 | |
| SCHEMBL8058856 | 0.79 | ADORA2A (0.45) | ALDH1A1HTTPIK3CAADORA2ASLC29A1 | |
| SCHEMBL1194461 | 0.77 | ADORA2A (0.39) | KDM4EALDH1A1PIK3CAPIK3R1ADORA2A | |
| SCHEMBL1192715 | 0.76 | PIK3CD (0.41) | KDM4EALDH1A1HTTADORA2APIK3CD | |
| SCHEMBL2673074 | 0.76 | PIK3CD (0.40) | KDM4EALDH1A1HTTADORA2APIK3CD | |
| SCHEMBL2619267 | 0.76 | HDAC1 (0.37) | KDM4EALDH1A1HTTPIK3CAHDAC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8394796-B2 | Bicyclic pyrimidine PI3K inhibitor compounds selective for P110 delta, and methods of use | GENENTECH, INC. (US) | 2013-03-12 | — | — | US | disclosed |
| US-20120178736-A1 | BICYCLIC PYRIMIDINE PI3K INHIBITOR COMPOUNDS SELECTIVE FOR P110 DELTA, AND METHODS OF USE | CASTANEDO GEORGETTE (US) | 2012-07-12 | — | — | US | disclosed |
| US-8173650-B2 | Bicyclic pyrimidine PI3K inhibitor compounds selective for P110 delta, and methods of use | GENENTECH, INC. (US) | 2012-05-08 | — | — | US | disclosed |
| US-20100305096-A1 | BICYCLIC PYRIMIDINE PI3K INHIBITOR COMPOUNDS SELECTIVE FOR P110 DELTA, AND METHODS OF USE | GENENTECH, INC. | 2010-12-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120178736-A1 | BICYCLIC PYRIMIDINE PI3K INHIBITOR COMPOUNDS SELECTIVE FOR P110 DELTA, AND METHODS OF USE | PIK3CA, PIK3R2, PIK3CD | KDM4E 4660/4885ALDH1A1 4438/4885HTT 4707/4885 |
| US-20100305096-A1 | BICYCLIC PYRIMIDINE PI3K INHIBITOR COMPOUNDS SELECTIVE FOR P110 DELTA, AND METHODS OF USE | PIK3CA, PIK3R2, PIK3CD | KDM4E 4647/4885ALDH1A1 4423/4885HTT 4741/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.